But we also highlighted some limitations of this tracer, including its relatively low affinity for tau aggregates in non-AD tauopathies and its off-target binding to neuromelanin, melanin and blood products [25, 30–32, 46]. The gene discussed is MAPT; the disease is tauopathy.